BR112021026462A2 - Composições e métodos para tratar distúrbios de cns - Google Patents
Composições e métodos para tratar distúrbios de cnsInfo
- Publication number
- BR112021026462A2 BR112021026462A2 BR112021026462A BR112021026462A BR112021026462A2 BR 112021026462 A2 BR112021026462 A2 BR 112021026462A2 BR 112021026462 A BR112021026462 A BR 112021026462A BR 112021026462 A BR112021026462 A BR 112021026462A BR 112021026462 A2 BR112021026462 A2 BR 112021026462A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- cns disorders
- treating cns
- vib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867618P | 2019-06-27 | 2019-06-27 | |
| PCT/US2020/040153 WO2020264509A1 (en) | 2019-06-27 | 2020-06-29 | Compositions and methods for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026462A2 true BR112021026462A2 (pt) | 2022-03-15 |
Family
ID=71728947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026462A BR112021026462A2 (pt) | 2019-06-27 | 2020-06-29 | Composições e métodos para tratar distúrbios de cns |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552829B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990469A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7787635B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220038680A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114391019A (cg-RX-API-DMAC7.html) |
| AR (1) | AR119305A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020302748A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026462A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143509A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289172A (cg-RX-API-DMAC7.html) |
| MX (3) | MX2021015942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI896547B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020264509A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| CN101585862B (zh) | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| SI3705488T1 (sl) | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| MY190408A (en) * | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CA3030420C (en) * | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| AU2018290348B2 (en) * | 2017-06-23 | 2024-04-04 | Ayikoe-Guy MENSAH-NYAGAN | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| EP3728285B1 (en) * | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| US12139508B2 (en) | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| IL312610B2 (en) * | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| CN111410678B (zh) | 2019-01-08 | 2023-02-28 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| WO2020210116A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210117A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| BR112021026447A2 (pt) | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
| EP4251634A1 (en) * | 2020-11-25 | 2023-10-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
-
2020
- 2020-06-29 JP JP2021577424A patent/JP7787635B2/ja active Active
- 2020-06-29 CN CN202080059463.9A patent/CN114391019A/zh active Pending
- 2020-06-29 MX MX2021015942A patent/MX2021015942A/es unknown
- 2020-06-29 TW TW109121938A patent/TWI896547B/zh active
- 2020-06-29 KR KR1020227002448A patent/KR20220038680A/ko active Pending
- 2020-06-29 US US17/620,226 patent/US12552829B2/en active Active
- 2020-06-29 BR BR112021026462A patent/BR112021026462A2/pt unknown
- 2020-06-29 AU AU2020302748A patent/AU2020302748A1/en not_active Abandoned
- 2020-06-29 CA CA3143509A patent/CA3143509A1/en active Pending
- 2020-06-29 EP EP20743476.2A patent/EP3990469A1/en active Pending
- 2020-06-29 WO PCT/US2020/040153 patent/WO2020264509A1/en not_active Ceased
- 2020-06-29 AR ARP200101836A patent/AR119305A1/es unknown
-
2021
- 2021-12-16 MX MX2024009926A patent/MX2024009926A/es unknown
- 2021-12-16 MX MX2024009925A patent/MX2024009925A/es unknown
- 2021-12-20 IL IL289172A patent/IL289172A/en unknown
-
2025
- 2025-01-05 JP JP2025000024A patent/JP2025060984A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL289172A (en) | 2022-02-01 |
| MX2021015942A (es) | 2022-04-18 |
| WO2020264509A1 (en) | 2020-12-30 |
| US20220380405A1 (en) | 2022-12-01 |
| CA3143509A1 (en) | 2020-12-30 |
| US20230303616A9 (en) | 2023-09-28 |
| EP3990469A1 (en) | 2022-05-04 |
| AU2020302748A1 (en) | 2022-01-06 |
| KR20220038680A (ko) | 2022-03-29 |
| MX2024009926A (es) | 2024-08-22 |
| US12552829B2 (en) | 2026-02-17 |
| JP2025060984A (ja) | 2025-04-10 |
| MX2024009925A (es) | 2024-08-22 |
| TWI896547B (zh) | 2025-09-11 |
| TW202114700A (zh) | 2021-04-16 |
| AR119305A1 (es) | 2021-12-09 |
| JP7787635B2 (ja) | 2025-12-17 |
| JP2022538299A (ja) | 2022-09-01 |
| CN114391019A (zh) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026445A2 (pt) | Composições e métodos para tratar distúrbios de cns | |
| MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2023001689A (es) | Inhibidores de bcl-2. | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| AR117814A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| BR112021022105A2 (pt) | Inibidores de cdk | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| BR112021026447A2 (pt) | Composições e métodos para tratamento de distúrbios de cns | |
| AR113908A1 (es) | Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| EA201791955A1 (ru) | ИНГИБИТОРЫ TGF-β | |
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| UA122528C2 (uk) | Сполуки, які модулюють fxr (nr1h4) | |
| DOP2023000251A (es) | Compuestos oligoméricos que inhiben la expresión de hsd17b13 | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| AR097773A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| BR112022012258A2 (pt) | Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025013997-1 PROTOCOLO 870250057285 EM 07/07/2025 10:27.O PEDIDO FOI DIVIDIDO NO BR122025013998-0 PROTOCOLO 870250057291 EM 07/07/2025 10:35. |